Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Robert G, Wilcox"'
Autor:
Rachel C. Orme, William A.E. Parker, Mark R. Thomas, Heather M. Judge, Kathleen Baster, Wael Sumaya, Kenneth P. Morgan, Hannah C. McMellon, James D. Richardson, Ever D. Grech, Nigel M. Wheeldon, Ian R. Hall, Javaid Iqbal, David Barmby, Julian P. Gunn, Robert F. Storey, Robert G. Wilcox (chair), John T. Walsh, William Smith, Allan Skene
Publikováno v:
Circulation.
Background: Ticagrelor has superior efficacy to clopidogrel in the management of acute coronary syndromes but has not been assessed in patients undergoing percutaneous coronary intervention for stable coronary artery disease. We compared the pharmaco
Autor:
Antonio Carlos Carvalho, Frans Van de Werf, Robert G. Wilcox, Miodrag Ostojic, Kurt Huber, Patrick Goldstein, Philippe Gabriel Steg, Paul W. Armstrong, Cynthia M. Westerhout, Sigrun Halvorsen, Anthony H. Gershlick
Publikováno v:
Heart. 101:692-698
Objectives Primary percutaneous coronary intervention (P-PCI) is the preferred reperfusion option in ST-elevation myocardial infarction, but its benefits become attenuated as time to its potential delivery becomes prolonged. Based on the STrategic Re
Autor:
Erich Bluhmki, Cynthia M. Westerhout, Patrick Goldstein, Philippe Gabriel Steg, Robert C. Welsh, Paul W. Armstrong, Frans Van de Werf, Renato D. Lopes, Robert G. Wilcox, Anthony H. Gershlick, Thierry Danays
Publikováno v:
The American Journal of Cardiology. 114:811-819
Although a fibrinolytic pharmacoinvasive strategy is recommended for patients with ST elevation myocardial infarction (STEMI) unable to undergo timely primary percutaneous coronary intervention (PCI), there are limited data addressing outcomes specif
Autor:
Robert G. Wilcox, G. Rosser, Pierluigi Tricoci, David A. Morrow, Maria Niespialowska-Steuden, C. Christopoulos, Diana A. Gorog, Robert Kozarski
Publikováno v:
Journal of Thrombosis and Thrombolysis. 38:423-429
To assess the effect of vorapaxar on global thrombotic and thrombolytic status. The propensity for thrombus formation is determined by the balance between prothrombotic factors and endogenous thrombolysis. Impaired thrombolytic status increases cardi
Autor:
AA Jennifer Adgey, Keith R. Abrams, Islam Zakareya Mahmoud, Vijay Kunadian, John P Greenwood, Daniel J. Blackman, Anthony H. Gershlick, Robert G. Wilcox, Gerry P McCann, Martin Been, Sheraz A Nazir, Jamal N Khan
Publikováno v:
Efficacy and Mechanism Evaluation, Vol 3, Iss 9 (2016)
BackgroundMicrovascular obstruction (MVO) predicts short- and longer-term outcomes following primary percutaneous coronary intervention (PPCI) treatment of ST-elevation myocardial infarction (STEMI). The evidence base supporting the role of adenosine
Autor:
Piera Angelica Merlini, Gaetano M. De Ferrari, Marc P. Bonaca, Eugene Braunwald, Michal Tendera, David A. Morrow, Robert G. Wilcox, Basil S. Lewis, Felix Mehrhof, Daniel Isaza, Frans Van de Werf, Benjamin M. Scirica, Sabina A. Murphy, Marc S. Sabatine
Publikováno v:
The Lancet. 380:1317-1324
Vorapaxar inhibits platelet activation by antagonising thrombin-mediated activation of the protease-activated receptor 1 on human platelets. The effect of adding other antiplatelet drugs to aspirin for long-term secondary prevention of thrombotic eve
Autor:
Gerry P McCann, Martin Been, Islam Zakareya Mahmoud, John P Greenwood, Daniel J. Blackman, Keith R. Abrams, Sheraz A Nazir, AA Jennifer Adgey, Anthony H. Gershlick, Vijay Kunadian, Robert G. Wilcox, Jamal N Khan, Lorraine Shipley
Publikováno v:
Nazir, S A, McCann, G P, Greenwood, J P, Kunadian, V, Khan, J N, Mahmoud, I Z, Blackman, D J, Been, M, Abrams, K R, Shipley, L, Wilcox, R, Adgey, A A J & Gershlick, A H 2016, ' Strategies to attenuate micro-vascular obstruction during P-PCI : the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial ', European Heart Journal, vol. 37, no. 24, pp. 1910-9 . https://doi.org/10.1093/eurheartj/ehw136
European Heart Journal
European Heart Journal
Background Microvascular obstruction (MVO) following primary percutaneous coronary intervention (PPCI) treatment of ST-segment elevation myocardial infarction (STEMI) contributes to infarct expansion, left ventricular (LV) remodelling, and worse clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ab5d5657627b584ae5c1b02ff77fa72
https://kclpure.kcl.ac.uk/ws/files/57360101/Strategies_to_attenuate_micro_vascular_NAZIR_Accepted_9Mar2016_GOLD_VoR.pdf
https://kclpure.kcl.ac.uk/ws/files/57360101/Strategies_to_attenuate_micro_vascular_NAZIR_Accepted_9Mar2016_GOLD_VoR.pdf
Autor:
Robert G. Wilcox, Jillian G. Baker
Publikováno v:
Thorax. 72(3)
Treating people with cardiovascular disease and COPD causes significant clinician anxiety. β-Blockers save lives in people with heart disease, specifically postinfarction and heart failure. COPD and heart disease frequently coexist and people with b
Autor:
Bernard Charbonnel, John A. Dormandy, Robert Spanheimer, Markku Laakso, Eleuterio Ferrannini, Erland Erdmann, Ralph A. DeFronzo, D. J. Betteridge, Robert G. Wilcox
Publikováno v:
Diabetes, Obesity and Metabolism. 13:759-764
Aim: In PROactive, pioglitazone reduced the incidence of death, myocardial infarction and stroke, and significantly improved HbA1c, systolic blood pressure (SBP), triglycerides and high-density lipoprotein (HDL)-cholesterol relative to placebo. As th
Autor:
Paul W. Armstrong, Robert C. Welsh, Robert M. Califf, Robert G. Wilcox, Frans Van de Werf, Cynthia M. Westerhout, Jeffrey A. Bakal
Publikováno v:
American Heart Journal. 161:848-854
Background Traditional time-to-event analysis assigns equal weight to the first event in the composite end point. This is counterintuitive to many stakeholders. Methods We constructed weights for components of a composite efficacy end point and a net